Wave Life Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $646.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $2.30M | $-0.34 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $17.20M | $-0.30 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $7.60M | $-0.32 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | Before market open | $8.70M | $-0.31 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $9.20M | $-0.29 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | Before market open | $83.70M | $0.17 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | Before market open | – | – | – |
Press releases
Announcements Wave Life Sciences filed with the SEC
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward-looking statements This document contains forward-looking
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward-looking statements This document contains forward-looking
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Announces Hearing on
Other events · EX-99.1 to Form 8-K
Wave Life Sciences Announces Proposed Redomiciliation to the
Material agreement · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Other events · EX-99.1 to Form 8-K
Wave Life Sciences Highlights Strategic Priorities for 2026 at the
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Corporate Presentation November 17, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 4, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 8, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K